JP2020526553A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020526553A5 JP2020526553A5 JP2020501279A JP2020501279A JP2020526553A5 JP 2020526553 A5 JP2020526553 A5 JP 2020526553A5 JP 2020501279 A JP2020501279 A JP 2020501279A JP 2020501279 A JP2020501279 A JP 2020501279A JP 2020526553 A5 JP2020526553 A5 JP 2020526553A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- aln
- composition according
- body weight
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023134504A JP7767365B2 (ja) | 2017-07-13 | 2023-08-22 | Ｈａｏ１（ヒドロキシ酸オキシダーゼ１（グリコール酸オキシダーゼ））遺伝子発現の阻害方法 |
| JP2025182212A JP2026035588A (ja) | 2017-07-13 | 2025-10-29 | Ｈａｏ１（ヒドロキシ酸オキシダーゼ１（グリコール酸オキシダーゼ））遺伝子発現の阻害方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762532176P | 2017-07-13 | 2017-07-13 | |
| US62/532,176 | 2017-07-13 | ||
| US201762581565P | 2017-11-03 | 2017-11-03 | |
| US62/581,565 | 2017-11-03 | ||
| US201862646285P | 2018-03-21 | 2018-03-21 | |
| US62/646,285 | 2018-03-21 | ||
| US201862682020P | 2018-06-07 | 2018-06-07 | |
| US62/682,020 | 2018-06-07 | ||
| PCT/US2018/041891 WO2019014491A1 (en) | 2017-07-13 | 2018-07-12 | METHODS OF INHIBITING GENE EXPRESSION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023134504A Division JP7767365B2 (ja) | 2017-07-13 | 2023-08-22 | Ｈａｏ１（ヒドロキシ酸オキシダーゼ１（グリコール酸オキシダーゼ））遺伝子発現の阻害方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020526553A JP2020526553A (ja) | 2020-08-31 |
| JP2020526553A5 true JP2020526553A5 (https=) | 2021-08-12 |
| JP7337044B2 JP7337044B2 (ja) | 2023-09-01 |
Family
ID=65002248
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020501279A Active JP7337044B2 (ja) | 2017-07-13 | 2018-07-12 | Ｈａｏ１（ヒドロキシ酸オキシダーゼ１（グリコール酸オキシダーゼ））遺伝子発現の阻害方法 |
| JP2023134504A Active JP7767365B2 (ja) | 2017-07-13 | 2023-08-22 | Ｈａｏ１（ヒドロキシ酸オキシダーゼ１（グリコール酸オキシダーゼ））遺伝子発現の阻害方法 |
| JP2025182212A Pending JP2026035588A (ja) | 2017-07-13 | 2025-10-29 | Ｈａｏ１（ヒドロキシ酸オキシダーゼ１（グリコール酸オキシダーゼ））遺伝子発現の阻害方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023134504A Active JP7767365B2 (ja) | 2017-07-13 | 2023-08-22 | Ｈａｏ１（ヒドロキシ酸オキシダーゼ１（グリコール酸オキシダーゼ））遺伝子発現の阻害方法 |
| JP2025182212A Pending JP2026035588A (ja) | 2017-07-13 | 2025-10-29 | Ｈａｏ１（ヒドロキシ酸オキシダーゼ１（グリコール酸オキシダーゼ））遺伝子発現の阻害方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11261447B2 (https=) |
| EP (1) | EP3651775A4 (https=) |
| JP (3) | JP7337044B2 (https=) |
| AU (2) | AU2018301829B2 (https=) |
| CA (1) | CA3069451A1 (https=) |
| WO (1) | WO2019014491A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202503057A (zh) | 2014-10-10 | 2025-01-16 | 美商艾爾妮蘭製藥公司 | 用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法 |
| EP3310918B1 (en) | 2015-06-18 | 2020-08-05 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof |
| CA3069451A1 (en) | 2017-07-13 | 2019-01-17 | Alnylam Pharmaceuticals, Inc. | Methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
| AU2020376792B2 (en) | 2019-11-01 | 2025-10-02 | Lilac Therapeutics, Inc. | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors |
| EP4121534A1 (en) * | 2020-03-18 | 2023-01-25 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant |
| CA3198823A1 (en) * | 2020-10-21 | 2022-04-28 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating primary hyperoxaluria |
| TW202237150A (zh) * | 2020-12-01 | 2022-10-01 | 美商艾拉倫製藥股份有限公司 | 用於抑制ｈａｏ１（羥基酸氧化酶１（乙醇酸氧化酶））基因表現的方法及組成物 |
| EP4043018A1 (en) | 2021-02-10 | 2022-08-17 | Charité - Universitätsmedizin Berlin | Composition and method for reducing oxalate levels in patients receiving maintenance dialysis |
| WO2023003805A1 (en) * | 2021-07-19 | 2023-01-26 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder |
| CN118460656B (zh) * | 2024-07-10 | 2024-12-06 | 凯莱英医药集团（天津）股份有限公司 | 一种Lumasiran的制备方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2429814C (en) | 2000-12-01 | 2014-02-18 | Thomas Tuschl | Rna interference mediating small rna molecules |
| EP1386004A4 (en) | 2001-04-05 | 2005-02-16 | Ribozyme Pharm Inc | MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID |
| US20050176025A1 (en) | 2001-05-18 | 2005-08-11 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA) |
| US20030170891A1 (en) | 2001-06-06 | 2003-09-11 | Mcswiggen James A. | RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| US7923547B2 (en) | 2002-09-05 | 2011-04-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| US9879266B2 (en) | 2002-11-14 | 2018-01-30 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| AU2003295600A1 (en) | 2002-11-14 | 2004-06-15 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| WO2004090108A2 (en) | 2003-04-03 | 2004-10-21 | Alnylam Pharmaceuticals | Irna conjugates |
| CA2518475C (en) | 2003-03-07 | 2014-12-23 | Alnylam Pharmaceuticals, Inc. | Irna agents comprising asymmetrical modifications |
| AU2004263830B2 (en) * | 2003-06-13 | 2008-12-18 | Alnylam Pharmaceuticals, Inc. | Double-stranded ribonucleic acid with increased effectiveness in an organism |
| CA2559955C (en) | 2004-03-15 | 2016-02-16 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded rna |
| US7642348B2 (en) | 2004-10-04 | 2010-01-05 | Rosetta Genomics Ltd | Prostate cancer-related nucleic acids |
| JP2008537551A (ja) | 2005-03-31 | 2008-09-18 | カランド ファーマシューティカルズ， インコーポレイテッド | リボヌクレオチドレダクターゼサブユニット２の阻害剤およびその使用 |
| NZ571568A (en) | 2006-03-31 | 2010-11-26 | Alnylam Pharmaceuticals Inc | Double-stranded RNA molecule compositions and methods for inhibiting expression of Eg5 gene |
| US8598333B2 (en) | 2006-05-26 | 2013-12-03 | Alnylam Pharmaceuticals, Inc. | SiRNA silencing of genes expressed in cancer |
| WO2009073809A2 (en) | 2007-12-04 | 2009-06-11 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
| US9051567B2 (en) | 2009-06-15 | 2015-06-09 | Tekmira Pharmaceuticals Corporation | Methods for increasing efficacy of lipid formulated siRNA |
| US20110045593A1 (en) | 2009-08-19 | 2011-02-24 | TransAlgae (Israel) Ltd. | Transgenically mitigating the establishment and spread of transgenic algae in natural ecosystems by suppressing the activity of carbonic anhydrase |
| SI2539451T1 (sl) | 2010-02-24 | 2016-04-29 | Arrowhead Research Corporation | Sestavki za ciljano dostavo sirna |
| US8945847B2 (en) | 2010-05-24 | 2015-02-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods and kits for ascertaining biosafety of an agent |
| EP3730618A1 (en) | 2011-11-18 | 2020-10-28 | Alnylam Pharmaceuticals, Inc. | Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases |
| SI3366775T2 (sl) | 2011-11-18 | 2025-12-31 | Alnylam Pharmaceuticals, Inc. | Modificirana sredstva RNAI |
| WO2013151665A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| AU2013299717B2 (en) | 2012-08-06 | 2018-06-28 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugated RNA agents and process for their preparation |
| IL288931B2 (en) | 2013-03-14 | 2025-05-01 | Alnylam Pharmaceuticals Inc | Compositions comprising a complementary portion of C5 IRNA and methods of using them |
| EP3581654B1 (en) | 2013-12-27 | 2021-03-31 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of glycolate oxidase (hao1) by double-stranded rna |
| TW202503057A (zh) | 2014-10-10 | 2025-01-16 | 美商艾爾妮蘭製藥公司 | 用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法 |
| EP3310918B1 (en) | 2015-06-18 | 2020-08-05 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof |
| WO2017048843A1 (en) * | 2015-09-14 | 2017-03-23 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the alas1 gene |
| CA3069451A1 (en) | 2017-07-13 | 2019-01-17 | Alnylam Pharmaceuticals, Inc. | Methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
-
2018
- 2018-07-12 CA CA3069451A patent/CA3069451A1/en active Pending
- 2018-07-12 US US16/630,800 patent/US11261447B2/en active Active
- 2018-07-12 WO PCT/US2018/041891 patent/WO2019014491A1/en not_active Ceased
- 2018-07-12 JP JP2020501279A patent/JP7337044B2/ja active Active
- 2018-07-12 AU AU2018301829A patent/AU2018301829B2/en active Active
- 2018-07-12 EP EP18831099.9A patent/EP3651775A4/en active Pending
-
2022
- 2022-01-20 US US17/579,655 patent/US20220403394A1/en active Pending
-
2023
- 2023-08-22 JP JP2023134504A patent/JP7767365B2/ja active Active
-
2024
- 2024-10-21 AU AU2024227498A patent/AU2024227498A1/en active Pending
-
2025
- 2025-10-29 JP JP2025182212A patent/JP2026035588A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020526553A5 (https=) | ||
| Wedemeyer et al. | Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection | |
| MX2023012450A (es) | Esketamina para el tratamiento de la depresion. | |
| JP2019509318A5 (https=) | ||
| JP2014530226A5 (https=) | ||
| JP2019196370A5 (https=) | ||
| JP2017502017A5 (https=) | ||
| JP2011519364A5 (https=) | ||
| EP4707394A3 (en) | Rnai agents for hepatitis b virus infection | |
| NO20090887L (no) | Fremgangsmate for behandling og forebygging av mukositt | |
| RU2015100529A (ru) | Способы лечения рака поджелудочной железы с применением комбинированной терапии, включающей липосомный иринотекан | |
| JP2016530279A5 (https=) | ||
| IL320452A (en) | Combination therapy for prostate cancer | |
| JP2018514510A5 (https=) | ||
| JP2018538306A5 (https=) | ||
| MX2022006742A (es) | Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter. | |
| TNSN06308A1 (en) | Macrocyclic compounds as inhibitors of viral replication | |
| FI3930686T3 (fi) | Uusia rautakoostumuksia ja menetelmiä niiden valmistamiseksi ja käyttämiseksi | |
| JP2022501332A5 (https=) | ||
| EA201101036A1 (ru) | Применение хлорида аммония в терапии | |
| JP2021004249A5 (https=) | ||
| JP2023510341A5 (ja) | ナルブフィン治療可能障害を治療するために投与されるナルブフィン製剤 | |
| MY193963A (en) | Composition for treating joint diseases and kit containing same | |
| FI3359572T3 (fi) | Menetelmä multippeliskleroosin hoitamiseksi | |
| JP2019535830A5 (https=) |